In Brief: Glaxo Wellcome
This article was originally published in The Tan Sheet
Executive Summary
Glaxo Wellcome: Appointing a U.S. chief operating officer is a priority for Glaxo Wellcome CEO Robert Ingram following his elevation to the chief exec spot, announced Oct. 28. Ingram keeps his position as head of the U.S. operating division of Glaxo (Glaxo Wellcome, Inc.) but will name a new chief operating officer as soon as possible. The lack of an immediate successor to handle the day-to-day operations of the company highlights the impression of suddenness surrounding Glaxo's announcement of Ingram's promotion. Ingram's appointment as CEO comes just five months after Sean Lance was named chief operating officer and CEO-designate of Glaxo Wellcome plc. Lance, "as a result of this decision, will be leaving the company after 12 years of outstanding service," Glaxo says. Lance's departure is not related to differences over strategic direction or to the performance of the company, Glaxo maintains...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning